A second drug has received approval as preexposure prophylaxis (PrEP) for HIV-1. The combination of emtricitabine and tenofovir alafenamide is indicated for men and transgender women who have sex with men. But the drug isn’t indicated for cisgender (those whose gender identity aligns with their birth sex) women because they weren’t included in an international clinical trial.
Voelker R. PrEP Drug Is Approved for Some Patients but Not for Others. JAMA. 2019;322(17):1644. doi:10.1001/jama.2019.17814
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: